NCPA commends U.S. Senate Finance Committee's approval of the Cantwell amendment

Published on September 26, 2009 at 1:40 AM · No Comments

The National Community Pharmacists Association (NCPA) today commended the U.S. Senate Finance Committee for approving by unanimous, voice vote an amendment by U.S. Sen. Maria Cantwell (D-WA) to lower health care costs through common-sense disclosure requirements for any pharmacy benefit manager (PBM) participating in the health insurance exchanges envisioned in Chairman Max Baucus’ (D-MT) America’s Healthy Future Act.

“PBMs routinely gobble up significant shares of nearly every prescription drug transaction, passing the costs on to patients and plan sponsors often left in the dark as premiums increase,” said Bruce T. Roberts, RPh, NCPA Executive Vice President and CEO. “Increasingly, public and private payers are rightly asking questions and demanding more equitable pharmacy benefit arrangements. Medicare, the Pentagon, state governments and major companies are all moving in this direction and today’s vote shows the Senate is, too. We commend Senator Cantwell for her leadership on this issue and we sincerely appreciate her colleagues’ support.”

The Cantwell amendment would require PBMs operating in a health insurance exchange to provide basic aggregate information so that health plan sponsors can make educated decisions about which PBM, if any, offers the best value for the plan and patients.

In July, the House Energy and Commerce Committee approved a similar amendment, authored by Rep. Anthony Weiner (D-NY), to its health reform plan (H.R. 3200). The Congressional Budget Office indicated to House staff that the disclosure provision would not increase federal spending.

Consumer groups also back PBM reform and, in June, a top government auditor testified that there's a “good chance” taxpayers and participants in the Federal Employee Health Benefits Program are “not getting a good deal because of the lack of transparency” by PBMs.

Posted in: Healthcare News

Tags: , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Filipino | Bahasa | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics